A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly

We developed a combined population PK model for PIP/TAZ across a broad range of patients covering the extremes of patient characteristics. This model can be used as a robust a priori model for Bayesian forecasting to achieve individualised dosing. The simulations indicate that adjustments based on the allometric theory as well as maturation and decline of CL of PIP may help the current dosing recommendations to provide consistent target attainment across patient populations.

Authors

Institutions

Publication Details

Journal
Clinical Pharmacokinetics
Published
2024-12-25
DOI
https://doi.org/10.1007/s40262-024-01460-6
Citations
6
Primary Topic
Antibiotics Pharmacokinetics and Efficacy
Type
article
Field-Weighted Citation Impact
2.69

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly

Jan J. De Waele, Céline Thibault, Douglas J. Eleveld, Michael Zöller et al.
6 citations
Clinical Pharmacokinetics
Antibiotics Pharmacokinetics and Efficacy
2.69
article

A Pooled Pharmacokinetic Analysis for Piperacillin/Tazobactam Across Different Patient Populations: From Premature Infants to the Elderly

Jan J. De Waele, Céline Thibault, Douglas J. Eleveld, Michael Zöller, Johannes Zander, Sutep Jaruratanasirikul, Andrew Alexander Udy, Pieter Colin, Jeroen V. Koomen, Jason A. Roberts, Evelyn Dhont, Robin Michelet, Michel Struys, Fekade B. Sime, Pieter De Cock, Caroline Damen, Danny Tsai, Daming Kong, Sofie Dhaese, Charlotte Kloft, Michael Cohen-Wolkowiez, Fabio Silvio Taccone, Abdulrazzaq Alobaid, Timothy Felton, Jeffrey Lipman
article en
6 citations

Abstract

We developed a combined population PK model for PIP/TAZ across a broad range of patients covering the extremes of patient characteristics. This model can be used as a robust a priori model for Bayesian forecasting to achieve individualised dosing. The simulations indicate that adjustments based on the allometric theory as well as maturation and decline of CL of PIP may help the current dosing recommendations to provide consistent target attainment across patient populations.

Clinical PharmacokineticsVol. 64(1)
Prince of Songkla University (TH), Université Libre de Bruxelles (BE), University Medical Center Groningen (NL), The University of Queensland (AU), University of Groningen (NL), Duke University (US), Université de Montpellier (FR), Royal Brisbane and Women's Hospital (AU), Ghent University Hospital (BE), The Alfred Hospital (AU), Centre Hospitalier Universitaire Sainte-Justine (CA), University of Manchester (GB), Ghent University (BE), Manchester University NHS Foundation Trust (GB), Saint John's Hospital (BE), Centre for Human Drug Research (NL), Alice Springs Hospital (AU), Université de Nîmes (FR), Freie Universität Berlin (DE)
China Scholarship Council
Zero hunger
Openalex Percentile: Top 10%
Antibiotics Pharmacokinetics and Efficacy
2.69
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.